|
Market Closed -
NYSE
06:00:00 12/09/26 am AEST
|
5-day change | 1st Jan Change | ||
| 2.640 USD | -3.30% |
|
-1.12% | +46.67% |
| 12/08 | Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 12/08 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | 11 | +316.67% | 2 | |||||
| 1,318.66 | +18.19% | 29 | ||||||
| 277.91 | +4.64% | 22 | ||||||
| 277.31 | +7.85% | 29 | ||||||
| 373.71 | +8.57% | 19 | ||||||
| 153.37 | +11.68% | 22 | ||||||
| 212.3 | +34.09% | 23 | ||||||
| 388.03 | +2.83% | 29 | ||||||
| 310.17 | +12.2% | 23 | ||||||
| 158.15 | +10.04% | 27 | ||||||
| 28.88 | +4.17% | 26 | ||||||
| 569.19 | +10.43% | 27 | ||||||
| 66.42 | +4.36% | 24 | ||||||
| 94.06 | +28.39% | 24 | ||||||
| 21.61 | +22.08% | 21 | ||||||
| 9,323.33 | +45.18% | 15 | ||||||
| 6,603.31 | +16.54% | 16 | ||||||
| 58.22 | +20.87% | 18 | ||||||
| 41.91 | +12.99% | 11 | ||||||
| 71.35 | +67.22% | 17 | ||||||
| Average | 1,017.94 | +32.95% | 21 | ||||||
| Weighted average by Cap. | 714.78 | +13.65% | 25 |
- Stock Market
- Stocks
- PLX Stock
- Sector Protalix BioTherapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
